



2025/2026 Coding & Payment Guide

Transcarotid Artery Revascularization (TCAR) is a minimally invasive procedure to treat carotid artery disease and reduce stroke risk. The ENROUTE® TCAR System accesses the carotid artery through a small neck incision. During the procedure, blood flow is temporarily reversed to prevent plaque dislodgement. A stent is then placed at the blockage site to stabilize plaque and prevent future strokes.

ICD-10-CM Diagnosis Codes

Physicians and hospitals use diagnosis codes to document the indication for TCAR procedures, including any additional diagnoses of other clinical conditions applicable to the patient's healthcare visit. Common diagnosis codes associated with TCAR procedures include:

ICD-10-CM Code	Code Description
165.[8,9]	Occlusion and stenosis of [other, unspecified] precerebral artery(ies)
I65.[21,22,23,29]	Occlusion and stenosis of [right, left, bilateral, unspecified] carotid artery, not resulting in cerebral infarction
I63.[131,132,133,139]	Cerebral infarction due to embolism of [right, left, bilateral, unspecified] carotid artery
I63.[031,032,033,039]	Cerebral infarction due to thrombus of [right, left, bilateral, unspecified] carotid artery
I63.[231,232,233,239]	Cerebral infarction due to unspecified occlusion or stenosis of [right, left, bilateral, unspecified] carotid arteries

Hospital Inpatient Coding & Payment

ICD-10-PCS Procedure Codes

Hospitals use ICD-10-PCS codes to report inpatient procedures. The ENROUTE® TCAR System has two distinct ICD-10-PCS codes: one for carotid stenting and another for reverse flow embolic neuroprotection. Use both ICD-10-PCS code sets to accurately reflect the procedure performed.

Procedure	ICD-10-PCS Code	Code Description
Carotid Stenting	037(H/J/K/L)3(D/E/F/G)Z	Percutaneous dilation of vessel using an intraluminal device
Reverse Flow Embolic Neuroprotection	5A05A6Q New code effective 10/1/25	Intraoperative Cerebral embolic filtration, extracorporeal flow reversal circuit

Fourth Character: H - Common Carotid Artery, Right, J - Common Carotid Artery, Left, K - Internal Carotid Artery, Right, L - Internal Carotid Artery, Left

Sixth Character: D - Intraluminal Device, E - Intraluminal Device (2), F - Intraluminal Device (3), G - Intraluminal Device (4+)

FY2026 MS-DRG Codes & Payments (effective October 1, 2025 – September 30, 2026)

Medicare reimburses TCAR as an inpatient procedure¹ using the Medicare Severity Diagnosis-Related Group (MS-DRG) system. Each inpatient stay is assigned a single MS-DRG based on the patient's diagnoses (ICD-10-CM) and procedures (ICD-10-PCS). The highest-ranked procedure code typically determines the assigned MS-DRG. Common MS-DRGs assigned for TCAR are included below.

Non-Medicare reimbursement for TCAR procedures may vary. Payment methods may include MS-DRG, case rates, percentage of billed charges, or device carve outs.

MS-DRG Code	Code Description	Medicare National Average ²	National Discharge Volume (%)³
034	Carotid Artery Stent Procedures with MCC	\$28,166	2,115 (12.8%)
035	Carotid Artery Stent Procedures with CC	\$17,395	6,071 (36.9%)
036	Carotid Artery Stent Procedures without CC/MCC	\$14,137	8,275 (50.3%)
	Weighted National Average⁴	\$17,141	16,461 (100%)

MS-DRG 034 represents Major Complications or Comorbidities (MCC), MS-DRG 035 represents Complications or Comorbidities (CC), and MS-DRG 036 represents neither CC nor MCC (CC/MCC).

HCPCS II Device Codes

HCPCS II codes may be utilized by some hospitals for internal tracking across different care settings, even when not used for billing. The HCPCS codes for the ENROUTE® TCAR System include:

Device	HCPCS C-Code	Device
ENROUTE® Transcarotid Neuroprotection System	C1884	Embolization protective system
ENROUTE® Transcarotid Stent System	C1876	Stent, non-coated/non-covered, with delivery system
ENROUTE Enflate® Transcarotid RX Balloon Dilatation Catheter	C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)
ENHANCE® Transcarotid Peripheral Access Kit	C1894	Introducer/Sheath, non-laser
ENROUTE® 0.014" Guidewire	C1769	Guidewire

¹ Medicare will continue to pay CPT code 37215 as a hospital inpatient only procedure in 2025. Addendum E.-- HCPCS Codes That Would Be Paid Only as Inpatient Procedures for calendar year 2025. https://www.cms.gov/license/ama?file=/files/zip/2025-nfrm-opps-addenda.zip

² Medicare payments to hospital inpatient are based on the FY 2026 Medicare Inpatient Prospective Payment System (IPPS), effective October 1, 2025 - September 30, 2026. Payments do not include the 2% sequestration reduction and are subject to change without notice. Actual hospital payments will vary. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2026-ipps-final-rule-home-page

³ After Outliers Removed (AOR) v43| CMS. Cms.gov. https://www.cms.gov/files/zip/fy2026-ipps-fr-aor-bor.zip

⁴ Weighted National Average represents the estimated average payment for all Carotid Artery Stent Procedures. It is calculated by considering the fiscal year 2026 payment for each MS-DRG within this group and the proportion of cases falling into each DRG in fiscal year 2024.

Physician Coding & Payment

CY2025 CPT® Codes⁵ & Payment (effective January 1, 2025 – December 31, 2025)

Physicians use Current Procedural Terminology (CPT) codes to describe the TCAR procedures performed. Proper documentation is crucial for selecting the correct CPT codes. The CPT codes below describe the procedures associated with the ENROUTE® TCAR System.

Medicare physician payments for TCAR procedures are determined using the Resource-Based Relative Value Scale (RBRVS) methodology. Each CPT code is assigned a relative value unit (RVU), which contributes to the final payment amount.

CPT Code	Code Description	Facility RVU		Medicare
		Work	Total	National Average ⁶
37215	Transcatheter placement of intravascular stent(s), cervical carotid artery, open or percutaneous, including angioplasty, when performed, and radiological supervision and interpretation; with distal embolic protection	17.75	29.01	\$938
76937-26	Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent real time ultrasound visualization of vascular needle entry, with permanent recording and reporting (List separately in addition to code for primary procedure)	0.30	0.40	\$13

Clinical Trial Numbers

The ENROUTE® TCAR System is covered under the National Coverage Determination (NCD) 20.7.7 For coverage under Section B3 (Concurrent with Carotid Stent Placement in FDA-Approved Post-Approval Studies), participation in an approved clinical study is required. The following studies are associated with Section B3 coverage, where study participation and accurate National Clinical Trial (NCT) number billing are mandatory8:

Study Title	Sponsor	National Clinical Trial (NCT) Number
SVS VQI TransCarotid Revascularization Surveillance Project (VQI TSP)	Society for Vascular Surgery	NCT02850588
The ROADSTER 3 Study	Silk Road Medical	NCT05365490

⁵ CPT copyright 2025 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

⁶ Medicare payments to physicians are based on the CY 2026 Medicare Physician Fee Schedule and effective January 1, 2025 - December 31, 2025. The conversion factor for CY 2025 is \$32.3465. Payments do not include the 2% sequestration reduction and are subject to change without notice. Actual physician payment will vary based on geographic location and may differ based on policies and fee schedules outlined in health plan and/or payer contracts. https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1807-f

⁷ NCD - Percutaneous Transluminal Angioplasty (PTA) (20.7). Cms.gov. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=201

⁸ Carotid Artery Stenting (CAS) Investigational Studies | CMS. Cms.gov. https://www.cms.gov/medicare/coverage/approved-facilities-trials-registries/carotid-artery-stenting-studies

Billing Requirements

Medicare has specific claim submission instructions for TCAR procedures, varying depending on the covered indication under NCD 20.7.9

- Section B3: Concurrent with Carotid Stent Placement in FDA-Approved Post-Approval Studies (e.g., SVS VQI TransCarotid Revascularization Surveillance Project (VQI TSP))
- Section B4: Concurrent with Carotid Stent Placement

See the tables below for claim submission instructions for hospitals and physicians. Section B3 provides instructions for providers participating in the VQI TSP, as an example of an approved clinical study.

Non-Medicare payers may have different billing requirements. Contact the payer directly to verify specific billing and claims submission requirements for carotid artery stent procedures.

Hospital Claims

Medicare Billing Requirements	Section B3	Section B4
Secondary Diagnosis Code	Z00.6 Encounter for examination for normal comparison and control in clinical research program ¹⁰	NA
Bill Type ¹	11X Inpatient	11X Inpatient
Condition Code	30 Qualifying clinical trial	NA
National Clinical Trial (NCT)	NCT02850588 is required for cases enrolled in the VQI TSP ¹¹	NA

Physician Claims

Medicare Billing Requirements	Section B3	Section B4
Secondary Diagnosis Code	Z00.6 Encounter for examination for normal comparison and control in clinical research program ¹⁰	NA
Modifier	Q0 Investigational service provided in a clinical research study that is in an approved clinical research study ¹²	NA
Place of Service ¹	21 Inpatient Hospital	21 Inpatient Hospital
National Clinical Trial (NCT)	NCT02850588 is required for cases enrolled in the VQI TSP ¹³	NA

⁹ Medicare Managed Care Manual Chapter 4 - Benefits and Beneficiary Protections. Cms.gov. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/mc86c04.pdf

¹⁰ ICD-10-CM diagnosis code Z00.6 is billed with NCT02850588.

¹¹ For institutional claims, 02850588 should be placed in the value amount of value code D4 on Form UB-40 (Form Locators 39-41) or in Loop 2300 REF02 (REF01=P4) in the electronic 837l.

¹² Modifier Q0 is appended to CPT code 37215 for professional claims submitted to Medicare or Medicare Advantage.

¹³ For professional claims, 02850588 should be preceded by "CT" and placed in Field 19 of Form CMS-1500 or it should be entered without the "CT" prefix in the electronic 837P in Loop 2300 REF02 (REF01=P4).

ENROUTE Transcarotid Stent System

INTENDED USE/INDICATIONS FOR USE The ENROUTE® Transcarotid Stent System used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) is indicated for the treatment of patients at high risk and standard risk for adverse events from carotid endarterectomy, who require carotid revascularization and meet the criteria outlined below: High Risk | Standard Risk With neurological symptoms: $\geq 50\%$ stenosis of the common or internal carotid artery by ultrasound or angiogram | $\geq 70\%$ stenosis of the common or internal carotid artery by angiogram Without neurological symptoms: $\geq 80\%$ stenosis of the common or internal carotid artery by ultrasound or angiogram | $\geq 70\%$ stenosis of the common or internal carotid artery by ultrasound or angiogram | $\geq 70\%$ stenosis of the common or internal carotid artery by ultrasound or $\geq 60\%$ stenosis of the common or internal carotid artery by angiogram Reference vessel diameter: Must be within 4.0 mm -9.0 mm at the target lesion Carotid bifurcation location: Minimum 5 cm above the clavicle to allow for placement of the ENROUTE Transcarotid

ENROUTE Transcarotid Neuroprotection System

INTENDED USE/INDICATIONS FOR USE The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis and who have appropriate anatomy described below: • Adequate femoral venous access • Common carotid artery reference diameter of at least 6 mm • Carotid bifurcation is a minimum of 5 cm above the clavicle as measured by duplex Doppler ultrasound (DUS) or computerized axial tomography (CT) angiography or magnetic resonance (MR) angiography.

Important Information

Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters.

Boston Scientific does not promote the use of its products outside their FDA-approved label. Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. All trademarks are the property of their respective owners.

The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options. This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for selecting the site of service and treatment modalities appropriate for the patient based on medically appropriate needs of that patient and the independent medical judgment of the HCP.

CPT Copyright 2025 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. All trademarks are the property of their respective owners.



Peripheral Interventions 300 Boston Scientifc Way Marlborough, MA 01752-1234 bostonscientific.com/reimbursement

> Medical Professionals srm-reimburse@bsci.com

© 2025 Boston Scientific Corporation or its affiliates. All rights reserved.

PI-2100914-AC | NOV 2025